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ABSTRACT
This paper presents epidemiological and control characteristics of yellow fever 
in Brazil, taking its wild and urban transmission cycles into consideration. 
No urban cases have been reported in Brazil since 1942, but urban yellow 
fever cases were reported in Paraguay in 2008, after more than 50 years 
without registered cases in the Americas. The two main objectives of yellow 
fever control programs in Brazil are to reduce the number of wild cases and 
to maintain zero incidence of urban cases. Although there is a consensus 
regarding control measures that should be applied in areas endemic for the 
wild form, this is not so in relation to areas infested by Aedes aegypti. The 
arguments for and against expansion of the vaccination area are discussed. 
Environmental and entomological studies are needed so that areas receptive 
to wild-type transmission can be recognized, even if they have been silent 
for many years.
DESCRIPTORS: Yellow Fever, prevention & control. Yellow Fever, 
epidemiology.
INTRODUCTION
Yellow fever is transmitted to human beings through the bites of infected 
mosquitoes of the genera Aedes, Haemagogus and Sabethes, and it currently 
occurs in central African countries and several countries in South America.1,9
From an exclusively epidemiological point of view, an urban cycle and a wild 
cycle of transmission can be differentiated. Etiologically, clinically, immu-
nologically and physiopathologically, the disease is the same. In the urban 
cycle, the disease is an anthroponosis, without recognized animal reservoirs of 
epidemiological importance. Aedes aegypti is its most important vector, both 
in South America and in Africa.2,3 Although Aedes albopictus is susceptible to 
infection by the yellow fever virus in the laboratory, it has never been found 
infected in nature.
Since 1942, there have not been any recorded occurrences of the urban cycle 
of yellow fever in Brazil. The last three cases were notifi ed in the municipality 
of Sena Madureira, Acre. The last major epidemic occurred in Rio de Janeiro 
in 1928 and 1929, with 738 recorded cases and 478 deaths.a Elsewhere in the 
Americas, the last epidemic was recorded in Trinidad and Tobago in 1954, which 
not only brought human distress and the direct expenses due to patient care 
but also brought large-scale economic losses relating to reductions in tourism 
and foreign trade.10 In 2008, based on epidemiological data, an outbreak of the 
urban form of the disease was recorded in Paraguay.b
a Franco O. A história da febre amarela no Brasil. Rio de Janeiro: Superintendên cia de 
Campanhas de Saúde Pública. Brasília: Ministério da Saúde; 1976.
b Organizacion Panamericana de la Salud. Brote de fi ebre amarilla en Paraguay. Bol Epidemiol. 
2008;27:1.
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In the wild cycle, yellow fever is a zoonosis that is trans-
mitted in the Americas by mosquitoes of two genera: 
Haemagogus (H. janthinomys and H. albomaculatus) 
and Sabethes, (S. chloropterus). The main source of 
infection is non-human primates, particularly monkeys 
of the genera Allouata, Cebus, Atelles and Callithrix.2 
Other mammals may act as reservoirs, such as certain 
marsupials and rodents.7 Non-immune humans may 
become accidentally infected through penetration into 
enzootic areas.
In 1955, Brazil achieved the elimination of Ae. aegypti 
mosquitoes (which are also the main transmission 
agents for dengue), from its territory after a campaign 
that lasted for more than 20 years. Another 17 countries 
in the Americas were also successful in this endeavor, 
as certifi ed by the Pan-American Health Organization.a 
However, Brazil and all these other countries subse-
quently suffered reinfestation. In 1967, signifi cant 
reinfestations occurred in Belém, Pará, and in São Luiz, 
Maranhão, and these were only eliminated in 1973. 
However, in 1976, starting from the port of Salvador, 
Bahia, there was reinfestation that, unfortunately, not 
was not eliminated but also propagated throughout the 
country.c Currently, data from the Ministry of Health 
(from 2007) reveal that this mosquito is present in more 
than 4,000 municipalities.
Preventive vaccines against the disease exist. In Brazil, 
since 1937, vaccine containing attenuated virus has 
been used. This consists of the strain 17-DD, which 
comes from samples of the African Asibi strain and 
does not present neurotropism and viscerotropism. It 
is cultivated in embryonated hens’ eggs. The vaccine 
is produced by the Bio-Manguinhos Laboratory of the 
Fundação Oswaldo Cruz (Ministry of Health), and it is 
very effective and relatively safe. Its protective effect 
starts on the tenth day after vaccination and continues 
for a minimum of ten years.
The contraindications for using the vaccine are the 
following: history of hypersensitivity to substances 
present in hens’ eggs, age less than six months, pregnancy 
(except in situations of epidemiological emergency), 
acute infectious disease with a febrile state (higher than 
38.5 ºC) and states of immunodepression.c
CRITICAL ASPECTS OF CONTROL
There are currently two challenges relating to yellow 
fever control in Brazil: 1. To reduce the incidence 
of wild-cycle cases of the disease, which cannot be 
eradicated because it is a zoonosis; and 2. To maintain 
zero incidence of urban-cycle cases, i.e. to prevent 
reurbanization of the disease. Regarding the fi rst of 
these challenges, there is a consensus that vaccination 
is required for all people living in and visiting endemic 
areas, although uncertainties still exist today regarding 
exactly which areas these are. In relation to the second 
of these challenges, there is unanimity regarding the 
need to combat the mosquito Ae. aegypti,4,6,9 but there is 
no consensus regarding the need to vaccinate the whole 
population of urban areas infested with Ae. aegypti and/
or Ae. albopictus.
The fi ght against Ae. aegypti includes institutional 
and behavioral measures. Public authorities have the 
responsibility to provide adequate water supplies and 
regular garbage collection; to establish municipal 
sanitary legislation relating to used tire dumps and 
scrap iron yards that are exposed to rain, and to inspect 
compliance with the legislation; to require that sand be 
placed in vases in cemeteries; to clean up vacant plots 
of land; and to apply larvicide to water accumulations 
that cannot be eliminated. Among the behavioral 
measures, there is a need for intensive sanitary educa-
tion with the aim of getting people to eliminate the 
mosquitoes’ preferred breeding sites, for example by 
keeping water tanks covered, keeping backyards clean, 
ensuring correct drainage from the water gutters of 
roofs, avoiding leaving receptacles exposed such that 
they might accumulate water and changing the water 
in fl owerpots and trays frequently.8
There is also a consensus regarding the need for 
effective epidemiological surveillance of suspected 
cases (individuals with febrile-jaundiced-hemorrhagic 
syndrome coming from areas endemic for wild-type 
yellow fever), in areas infested with Ae. aegypti. 
Moreover, there is a consensus regarding the need for 
sanitary surveillance at ports, airports and borders, 
with the purpose of requiring presentation of a valid 
International Vaccination Certificate, by travelers 
coming from areas that are endemic for the disease. 
Likewise, there is full agreement regarding the need to 
keep suspected patients in isolation during the period 
of viremia, in order to avoid infecting Ae. aegypti and/
or Ae. albopictus mosquitoes that might be present in 
the area.
There is no agreement regarding vaccination of the 
populations living in areas infested with Ae. aegypti 
and/or Ae. albopictus, especially since certain very 
relevant recent events. People who declare that they are 
against geographical expansion of vaccination coverage 
base their view on the importance of four occurrences 
of death associated with the vaccine: one in Goiânia, 
GO, in 1999; one in Americana, SP, in March 2000;10 
one in Jaboticatubas, MG, in March 2001; and one 
in Três Passos, RS, in September 2001.d Additional 
c Ministério da Saúde. Fundação Nacional de Saúde. Manual de vigilância epidemiológica da febre amarela [internet]. Brasília; 1999 [cited 
2009 Sep 29]. Available from: http://portal.saude.gov.br/portal/arquivos/pdf/manu_feam.pdf
d Ministério da Saúde. Secretaria de Vigilância em Saúde. Coordenação Nacional de Imunização. Unpublished data.
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deaths associated with the vaccine were found in 2008 
and 2009, during the intensifi cation of vaccination in 
the states of São Paulo and Rio Grande do Sul. In the 
literature, there are reports on cases of death associated 
with the vaccine in the United States and Australia.5 
The factors that lead some people to present severe 
adverse events that are associated with the vaccine are 
still not fully understood. In addition to the contrain-
dications already mentioned, there are individual 
immune factors that so far remain unidentifi ed and fail 
to impede uncontrolled replication of the vaccine virus, 
thus reproducing the disease.10 Since the vaccine is not 
completely harmless, indiscriminate use of the vaccine 
among populations in areas infested with Ae. aegypti 
and/or Ae. albopictus should only take place when there 
is a high risk of urban transmission. Improvements 
in epidemiological surveillance might, up to a point, 
enable early detection of outbreaks, thereby making it 
possible to rapidly institute blocking vaccination.
People who declare that they are in favor of expanding 
the present area of vaccination coverage base their 
view on the fact that wild-type yellow fever transmis-
sion was detected in regions of the states of Bahia and 
São Paulo in 2000, and Minas Gerais in 2001, which 
presented infestation with Ae. aegypti but had not 
presented autochthonous cases of the wild form for 
many years. Also in 2001, in the western region of Rio 
Grande do Sul, virus circulation was detected through 
the deaths of monkeys, with laboratory confi rmation. 
In that region too, there had not been any records of 
epizootic yellow fever for more than 20 years. There is 
no doubt that the areas at risk of occurrences of wild-
type yellow fever in Brazil are expanding. In 2008, in 
regions of the states of São Paulo and Rio Grande do 
Sul that had not been considered to be areas with virus 
circulation, deaths of non-human primates and cases 
and deaths among humans were recorded. These events 
have expanded the areas within which vaccination for 
people living there and travelers going there is recom-
mended. Given the proximity of locations of human 
yellow fever occurrences to areas infested with Ae. 
aegypti, it is increasingly diffi cult to identify whether 
the cases recorded were transmitted by wild or urban 
vectors. Many researchers and healthcare professionals 
favor gradual expansion of the areas of vaccination 
coverage in Brazil, in view of the following points: 
1. Recommendations for vaccination only after cases 
and deaths have been recorded in such areas should be 
avoided; 2. The risk of urban transmission of the disease 
needs to be reduced, given the immense dispersion of 
Ae. aegypti and Ae. albopictus and the recent episode 
that occurred in Paraguay; 3. The worldwide scarcity 
of vaccine that could be used for urgent vaccination of 
populations in large urban centers if a disease outbreak 
occurred, either transmitted by Ae. aegypti, or resulting 
from a wild cycle on the periphery of these centers; 
4. The diffi culty in achieving timely vaccination (ten 
days before traveling) among tourists and migrants to 
areas with virus circulation; 5. Occurrences of serious 
adverse events associated with the vaccine have mainly 
been registered at the time of implementing vaccination 
in situations when thousands of people make demands 
on vaccination units within a short space of time 
and contraindications are often not respected; 6. The 
risk of adverse events is often greater among people 
receiving the vaccine for the fi rst time than among 
revaccinated individuals, and this is the situation of 
the vast majority of people living in areas that are not 
considered endemic. Initially, the vaccine should be 
included in the child immunization calendar throughout 
the country and should be applied to people living in 
and visitors to areas that are characterized as receptive 
to transmission of the wild cycle of the disease, even if 
these areas have been silent for many years.
Choosing only to perform blocking vaccination in 
emergency situations is a strategy advocated by people 
who are against geographical expansion of vaccina-
tion coverage. This strategy is criticized by those who 
advocate expansion of the coverage, on the grounds 
that on such occasions, mass vaccination of thousands 
of individuals would be required over a short space of 
time, and that this would result in some of the problems 
already cited, such as: scarcity of vaccine in unplanned 
situations, which was observed recently in the outbreak 
of urban yellow fever in Paraguay; and an exponential 
increase in the number of serious adverse effects associ-
ated with the vaccine, because it becomes diffi cult to 
identify and respect contraindications for vaccination. 
The risk of occurrence of such adverse effects is much 
greater among individuals receiving vaccination for the 
fi rst time, which is the situation of the vast majority of 
people in areas that are not considered endemic.
In view of this controversy, there is a growing need to 
delimit the areas that are receptive towards transmission 
of the wild cycle of the disease, even if such areas have 
been silent for many years. This delimitation involves 
conducting environmental, entomological and animal 
reservoir studies. Based on evidence of receptiveness, 
recommendations to vaccinate in such areas would 
avoid the situations of public health emergency that 
have been experienced over the past decade, during 
which vaccination areas were only expanded after 
observing epizootic disease among monkeys or cases 
and deaths among humans.
In conclusion, if on the one hand there are strong argu-
ments against the expansion of routine vaccination 
against yellow fever in areas in which the risk of serious 
events subsequent to vaccination is greater than the 
risk of acquiring the disease itself; on the other hand, 
the recent expansion of the area of wild-type yellow 
fever transmission and the overlapping of the presence 
of wild-cycle and urban-cycle vectors would speak in 
favor of the need to expand the vaccination coverage to 
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protect individuals living in or traveling to these areas. 
There is an urgent need for ecological and epidemio-
logical assessments in areas that are considered non-
epidemic, so that decisions can be made based on the 
best evidence possible. There is also a need for studies 
that might lead to identifying individual factors that 
predict occurrences of severe and lethal forms of the 
disease that are associated with vaccine use.
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